CRISPR-mediated Gene Editing Using a cGMP-Compliant Non-viral Cell Engineering: From iPSC Disease Modeling to Clinically-Meaningful Correction of Monogenic Disease Mutations in Patient Cells

2021-10-11T22:37:24+00:00May 12th, 2020|Comments Off on CRISPR-mediated Gene Editing Using a cGMP-Compliant Non-viral Cell Engineering: From iPSC Disease Modeling to Clinically-Meaningful Correction of Monogenic Disease Mutations in Patient Cells

High Throughput Transfection of Stem Cells, Primary Cells and Difficult-to-Transfect Cell Lines: Jurkat, CHO, Human Skeletal Muscle Cells & Primary Neuronal Cell Transfection using a Scalable, Electroporation-Based Technology

2021-10-01T17:53:00+00:00May 12th, 2020|Comments Off on High Throughput Transfection of Stem Cells, Primary Cells and Difficult-to-Transfect Cell Lines: Jurkat, CHO, Human Skeletal Muscle Cells & Primary Neuronal Cell Transfection using a Scalable, Electroporation-Based Technology

Advancing Next Generation Cell and Gene Therapies to the Clinic Using Non-viral, Scalable Engineering and Genome Modification of Human Primary Cells, Stem Cells and iPSCs.

2020-07-07T17:05:49+00:00May 12th, 2020|0 Comments

GMP-compliant Non-viral CRISPR-mediated Process Correcting the Sickle Cell Disease Mutation in SCD Patient CD34+ Cells Achieves 60% Wild Type Adult Hemoglobin Expression in Differentiated Erythrocytes.

2020-07-07T22:14:04+00:00May 12th, 2020|Comments Off on GMP-compliant Non-viral CRISPR-mediated Process Correcting the Sickle Cell Disease Mutation in SCD Patient CD34+ Cells Achieves 60% Wild Type Adult Hemoglobin Expression in Differentiated Erythrocytes.

Extracellular nanovesicles for packaging of CRISPRCas9 protein and sgRNA to induce therapeutic exon skipping

2021-10-04T16:13:45+00:00March 13th, 2020|Comments Off on Extracellular nanovesicles for packaging of CRISPRCas9 protein and sgRNA to induce therapeutic exon skipping
Go to Top